Document Detail


Proteomics-based prediction of clinical response in acute myeloid leukemia.
MedLine Citation:
PMID:  19422784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Response to chemotherapy is achieved in 60% to 70% of patients with acute myeloid leukemia. The ability to predict responders may help in stratifying patients and exploring different therapeutic approaches for nonresponders. Proteomics methods were used to search for predictive factors or combinations of factors.
MATERIALS AND METHODS: Peripheral blood plasma samples from 41 patients with confirmed acute myeloid leukemia with intermediate or poor cytogenetics were obtained prior to induction therapy for proteomic analysis. For each plasma sample, four fractions eluted from a strong anion column were applied to 3 different ProteinChip array surfaces and 12 surface-enhanced laser desorption/ionization spectra were generated. Peaks that correlated with response were identified, and decision trees incorporating these peaks along with various clinical and laboratory findings were constructed to predict response.
RESULTS: Multiple decision trees were constructed. One peak, when combined with age, provided strong positive prediction of responders with 83% accuracy. A second tree, which combined one peak with both cytogenetics and the percent of monocytes in peripheral blood, detected responders with 95% accuracy. A third peak was adequate to predict responders in the intermediate cytogenetic group with 86% accuracy.
CONCLUSIONS: Proteomic analysis should be further explored to define factors important in predicting clinical response in patients with acute myeloid leukemia.
Authors:
Maher Albitar; Steven J Potts; Francis J Giles; Susan O'Brien; Iman Jilani; Amber C Donahue; Elihu H Estey; Hagop Kantarjian
Related Documents :
8916934 - Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase...
2154924 - Recombinant gamma-interferon has activity in chronic myeloid leukemia.
6850654 - High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.
11342314 - Screening of bcr-abl transcripts in philadelphia negative essential thrombocythemia.
18019394 - Diet with lpp for renal patients increases daily energy expenditure and improves motor ...
12767094 - Serum s100beta: a noninvasive marker of blood-brain barrier function and brain lesions.
Publication Detail:
Type:  Journal Article     Date:  2009-05-05
Journal Detail:
Title:  Experimental hematology     Volume:  37     ISSN:  1873-2399     ISO Abbreviation:  Exp. Hematol.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-22     Completed Date:  2009-07-14     Revised Date:  2014-10-03    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  784-90     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use
Humans
Leukemia, Myeloid, Acute / drug therapy*,  metabolism,  pathology
Proteomics*
Reproducibility of Results
Grant Support
ID/Acronym/Agency:
P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Avian influenza A(H5N1)--current situation.
Next Document:  Cardiolipin, a critical determinant of mitochondrial carrier protein assembly and function.